Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
McKinsey
Cerilliant
Queensland Health
McKesson
Mallinckrodt
Harvard Business School
Chubb

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021241

« Back to Dashboard

NDA 021241 describes ORTHO TRI-CYCLEN LO, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the ORTHO TRI-CYCLEN LO profile page.

The generic ingredient in ORTHO TRI-CYCLEN LO is ethinyl estradiol; norgestimate. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestimate profile page.
Summary for 021241
Tradename:ORTHO TRI-CYCLEN LO
Applicant:Janssen Pharms
Ingredient:ethinyl estradiol; norgestimate
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021241
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241 NDA Janssen Pharmaceuticals, Inc. 50458-251 N 50458-251-06
ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241 NDA Janssen Pharmaceuticals, Inc. 50458-251 N 50458-251-12

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORAL-28Strength0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG
Approval Date:Aug 22, 2002TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Dec 9, 2019Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021241

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241-001 Aug 22, 2002 ➤ Sign Up ➤ Sign Up
Janssen Pharms ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241-001 Aug 22, 2002 ➤ Sign Up ➤ Sign Up
Janssen Pharms ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241-001 Aug 22, 2002 ➤ Sign Up ➤ Sign Up
Janssen Pharms ORTHO TRI-CYCLEN LO ethinyl estradiol; norgestimate TABLET;ORAL-28 021241-001 Aug 22, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Citi
Julphar
UBS
Baxter
Teva
Johnson and Johnson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.